Humira (adalimumab) / AbbVie 
Welcome,         Profile    Billing    Logout  
 200 Diseases   191 Trials   191 Trials   19915 News 


«12345678910111213...203204»
  • ||||||||||  Humira (adalimumab) / AbbVie
    Journal:  Case 328. (Pubmed Central) -  Apr 30, 2024   
    inhibitor (adalimumab), which was effective for pain, the patient was lost to follow-up...Routine blood tests revealed a normal blood cell count, creatinine level of 0.64 mg/dL (56.58 ?mol/L) (normal range, 0.30-1.1 mg/dL [26.52-97.24 mmol/L]), C-reactive protein level of 1.1 mg/dL (normal, <1 mg/dL), and vitamin D level of 21 ng/mL (52.42 nmol/L) (normal range, 30-100 ng/mL [74.88-249.60 nmol/L]). Noncontrast MRI of the thoracic and lumbar spine (Fig 2), MRI of the sacroiliac joints (Fig 3), and CT of the abdomen and pelvis (Fig 4) were performed.
  • ||||||||||  Humira (adalimumab) / AbbVie
    Biomarker, Clinical, Preclinical, Retrospective data, Review, Journal:  Recalcitrant folliculitis decalvans successfully controlled with adalimumab. (Pubmed Central) -  Apr 30, 2024   
    Noncontrast MRI of the thoracic and lumbar spine (Fig 2), MRI of the sacroiliac joints (Fig 3), and CT of the abdomen and pelvis (Fig 4) were performed. No abstract available
  • ||||||||||  Humira (adalimumab) / AbbVie
    Journal, IO biomarker:  Effect of adalimumab as an anti-inflammatory agent on gene expression of retinal pigment epithelial cells. (Pubmed Central) -  Apr 30, 2024   
    In conclusion, despite its safety, the 2x concentration of ADA was the only dose that did not ignite the expression of any of the studied inflammatory and fibrogenesis genes. This dosage, which is roughly equal to 2?mg intravitreal dose in a clinical setting, might be referred to as a reference starting point for future in-vivo studies in ocular conditions.
  • ||||||||||  Cosentyx (secukinumab) / Novartis
    Review, Journal:  An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa. (Pubmed Central) -  Apr 29, 2024   
    Overall, secukinumab has shown good efficacy and a favorable side effect profile in HS clinical trials but may be avoided in patients with inflammatory bowel disease. Long term and real-life data on the use of secukinumab are essential for improving decision-making in HS therapy.
  • ||||||||||  Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
    Journal:  Vitiligo as a First Sign of Vogt-Koyanagi-Harada Disease. (Pubmed Central) -  Apr 27, 2024   
    Immunosuppressive therapy with cyclosporine and/or azathioprine is considered if the symptoms are persistent or worsening. In case of no improvement, biological agents such as infliximab and adalimumab are included (4).
  • ||||||||||  Humira (adalimumab) / AbbVie
    Journal:  Vitiligo in a Patient Receiving Adalimumab for Idiopathic Uveitis. (Pubmed Central) -  Apr 26, 2024   
    As the inflammation did not resolve with local treatment, systemic cyclosporine was administered, after which the patient exhibited vomiting and weakness...Due to the persistence of intraocular inflammation and on the recommendation of the dermatology clinic, adalimumab treatment was continued and topical tacrolimus was started for the lesion...Taken together with the previous literature findings, no pathology was found in the patient's systemic examination, suggesting that this lesion was a side effect of the treatment. Ophthalmologists should be alert for this side effect in patients receiving adalimumab.
  • ||||||||||  Biomarker, Review, Journal:  Precision Dermatology: A Review of Molecular Biomarkers and Personalized Therapies. (Pubmed Central) -  Apr 26, 2024   
    In HS, TNF-?, IL-1?, and MMPs serve as biomarkers, influencing targeted therapies like adalimumab and anakinra...AD biomarkers include ECP, IL-4, IL-13, guiding therapies like dupilumab and tralokinumab...CSU biomarkers encompass IgE, cytokines, and autologous serum tests, influencing therapies like omalizumab and cyclosporine...Precision medicine, driven by biomarkers, has shown success in skin malignancies. Future directions involve AI-powered algorithms, nanotechnology, and multi-omics integration for personalized dermatological care.
  • ||||||||||  Humira (adalimumab) / AbbVie
    Review, Journal, Surgery, Post-surgery:  Maintaining remission in Crohn's disease post surgery: what can we learn from Cochrane? (Pubmed Central) -  Apr 26, 2024   
    The use of the evidence, including the Grading of Recomendations, Assessment, Development, and Evaluations (GRADE) certainty and magnitude of effect data, can support discussions with patients. Future research is needed to consider other therapies that are effective in medically induced maintenance given the low certainty of evidence limiting conclusions, either supporting or refuting their use.
  • ||||||||||  Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / AbbVie
    Clinical, Journal:  Development of an MRI-based prediction model for anti-TNF treatment failure in perianal Crohn's disease: A multicenter study. (Pubmed Central) -  Apr 25, 2024   
    Future research is needed to consider other therapies that are effective in medically induced maintenance given the low certainty of evidence limiting conclusions, either supporting or refuting their use. Our risk prediction models consisting of clinical and/or radiologic variables accurately predict treatment failure in patients with PAF.
  • ||||||||||  sonelokimab (M1095) / Avillion, MoonLake Immunotherap
    Trial completion:  Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis (clinicaltrials.gov) -  Apr 25, 2024   
    P2,  N=207, Completed, 
    Therefore, we believe that a combination of secukinumab with acitretin may be a rational approach for the treatment of severe GPP. Active, not recruiting --> Completed
  • ||||||||||  Remicade (infliximab) / J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
    Immunosuppressant drug-associated skin cancer: A real-world pharmacovigilance database analysis. () -  Apr 24, 2024 - Abstract #ASCO2024ASCO_4963;    
    While methotrexate use is known to possess an increased risk, it had the lowest odds of skin cancer compared to other drugs in the study. Prospective studies are needed to understand the true incidence of skin cancer associated with the use of immunosuppressant drugs.
  • ||||||||||  Humira (adalimumab) / AbbVie
    Journal:  National trends in prescription drug expenditures and projections for 2024. (Pubmed Central) -  Apr 24, 2024   
    For 2024, we expect overall prescription drug spending to rise by 10.0% to 12.0%, whereas in clinics and hospitals we anticipate an 11.0% to 13.0% increase and a 0% to 2.0% increase, respectively, compared to 2023. These national estimates of future pharmaceutical expenditure growth may not be representative of any health system because of the myriad of local factors that influence actual spending.
  • ||||||||||  Journal:  Baseline Characteristics and mNAPSI Change from Baseline Scores Through Month (Pubmed Central) -  Apr 23, 2024   
    Subfoveal choroidal thickness, indocyanine green angiography scores, and corticosteroid and cyclosporine doses were significantly reduced by ADA treatment for 6 This real-world study showed that patients with moderate-to-severe psoriasis and any severity of concomitant nail involvement had significantly faster and more substantial improvements in nail psoriasis up to month
  • ||||||||||  Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
    Review, Journal:  De-escalation of biological treatment in inflammatory bowel disease: A comprehensive review. (Pubmed Central) -  Apr 23, 2024   
    This real-world study showed that patients with moderate-to-severe psoriasis and any severity of concomitant nail involvement had significantly faster and more substantial improvements in nail psoriasis up to month Any consideration for de-escalation of biologic therapy in IBD must be tailored, taking into account the risks and consequences of a flare and patients' preferences.
  • ||||||||||  Humira (adalimumab) / AbbVie
    Journal:  Cochlear implantation in patients with autoimmune hearing loss (Pubmed Central) -  Apr 22, 2024   
    Further research is needed to identify potential blood-based biomarkers predictive of response to anti-TNF therapy in patients with inflammatory bowel disease. Cochlear implantation can be necessary in some AIED patients and poses a
  • ||||||||||  Stelara (ustekinumab) / J&J
    Allergy to Ustekinumab  (Poster Zone) -  Apr 21, 2024 - Abstract #EAACI2024EAACI_1348;    
    This case report underscores the growing concern regarding mAB hypersensitivity and the need for accurate diagnosis and therapeutic interventions. Skin testing, especially for type I and IV hypersensitivity reactions, may be valuable but standardized testing protocols are still lacking for most mABs.
  • ||||||||||  Journal:  Drug therapy in juvenile spondyloarthritis. (Pubmed Central) -  Apr 19, 2024   
    Long-term follow-up studies continue to demonstrate acceptable safety profiles. There is need for more real-world data on drug efficacy from Registry studies and research on effective de-escalation strategies.
  • ||||||||||  Humira SC (adalimumab/hyaluronidase) / AbbVie, Humira (adalimumab) / AbbVie
    Journal:  Surgical management of a case of non-resolving bullous retinal detachment due to probable Vogt-Koyanagi-Harada syndrome. (Pubmed Central) -  Apr 17, 2024   
    He was found to have bullous retinal detachment (RD) in the right eye and was started on subcutaneous adalimumab with oral corticosteroid following three doses of pulse corticosteroid...The patient has been under follow-up with us for the last one year now and developed no recurrence of RD till now. This case emphasises the significance of retinoretinal adhesion in long-standing bullous RD that does not respond to conventional aggressive medical therapy.
  • ||||||||||  Humira (adalimumab) / AbbVie
    Journal:  Use of biologics for psoriasis in solid organ transplant recipients. (Pubmed Central) -  Apr 16, 2024   
    We also reviewed literature in solid organ transplant patients with psoriasis. Our findings, based on 10 articles, indicate a cautious approach to using biologics in this group, with further research needed for efficacy and safety.
  • ||||||||||  Trial completion date, Trial primary completion date, Metastases:  Stand UP to Rheumatoid Arthritis (SUPRA) (clinicaltrials.gov) -  Apr 16, 2024   
    P=N/A,  N=75, Recruiting, 
    Our findings, based on 10 articles, indicate a cautious approach to using biologics in this group, with further research needed for efficacy and safety. Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
  • ||||||||||  Humira (adalimumab) / AbbVie
    Journal, Immunomodulating, Stroma:  Activated and Na (Pubmed Central) -  Apr 12, 2024   
    No abstract available The PBMCs of patients with HS were co-cultured with na